WWW goes WWWW: Searching is now sorted! The Web 2.0 for real

Transinsight, provider of knowledge-based software solutions, has released a new online version of the well-known life-science search engine www.GoPubMed.org. This, the first semantic search engine, reduces search time by up to 90%. By sorting search results it enables scientists to answer biomedical questions in completely new way.

The latest version of the search machine sorts all relevant documents to the top level categories What, Who, Where and When. This way, for the first time in search history, it is possible to design searches on both content and metadata in a seamlessly integrated way. Dr. Michael R. Alvers, CEO of Transinsight, points out that the opportunity for a user to rank the search results according to personal needs is revolutionary. "We don't rank, the user does!" says Alvers. "With our semantic technology we put the user at the centre of the search. Ranking algorithms like Google's PageRank are not relevant for us anymore since with our search technology the user is in the driver's seat. Also the folksonomy feature to curate matches is new and makes the Web 2.0 now and here!" continues Alvers enthusiastic.

Classical search engines are successful in helping users find information based on keywords. But they are not successful in answering complex questions. Knowledge searches are needed to answer the complex questions which are so predominant in the life sciences. Knowledge, however, is hardly ever used in traditional search engines. The new version of the search engine GoPubMed is based on two knowledge networks containing more than 120,000 terms: Gene Ontology (GO) and the Medical subject headings (MeSH). This allows biologists and medical doctors to find the needle in the haystack in both the bio-molecular and the medical domains.

"In GoPubMed the search is sorted; sorting documents into highly organised networks such as GO and MeSH facilitates the finding of relevant documents and the answering of questions with significant ease!" says Michael Schroeder, Professor for Bioinformatics at TU Dresden and CSO and Co‑Founder of Transinsight. "The use of GoPubMed can result in time savings of up to 90%. Consider the search for Aspirin, for example. With other search engines one gets more than 40,000 results for this term; by using GoPubMed's subtle mechanism for refining searches these 40,000 can be reduced to the 9 relevant to, say, coronary thrombosis. Finding these 9 articles with traditional technology takes several hours and the searcher has to have enormous knowledge in the field of coronary thrombosis. With GoPubMed even untrained students find these relevant articles within 3 seconds."

This enormous potential has been experienced not only in academia but also by big enterprises like Unilever, Elsevier, Statoil and Shell. The time these companies save with Transinsight's technology can now be used to act, instead of performing tedious searches.

"It is quite impressive to see the progress in GoPubMed. The possibility to seamlessly search PubMed, the web, the local desktop and corporate intranets on base of a knowledge-base makes the Web 2.0 reality for biologists and medical doctors" says David Ruslan, provider of www.WorldPharmaNews.com.

About Transinsight
Founded in 2005, Transinsight is focused on software solutions for the life sciences providing products for knowledge-based technologies. The flagship product, www.GoPubMed.org, a well established biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. Transinsight is headquartered in one of the leading German biotech incubators, the BioInnovationCenter Dresden BIOZ, where science and business work under one roof. Transinsight works in close collaboration with the Technical University Dresden.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...